Dupixent Mass Tort Marketing & Case Acquisition

The litigation landscape

The core fact pattern gives the litigation its shape: CTCL is routinely misdiagnosed as eczema or atopic dermatitis for years, and plaintiffs allege that treating that misdiagnosed population with an immune-modulating biologic delayed the true diagnosis while the lymphoma advanced. Because Dupixent's prescribing base runs into the millions worldwide, even a rare alleged effect defines a meaningful claimant population.

The docket is early — individual filings rather than consolidation — which historically is when firms build inventory at the most favorable economics, before the tort has a national advertising footprint.

See how this docket is trending on TortIntel's Dupixent page, updated as new filings come in.

Who a campaign targets

Screening criteria firms typically evaluate in Dupixent matters include:

• Documented Dupixent use, most commonly for eczema or atopic dermatitis
• A subsequent CTCL or related lymphoma diagnosis, particularly where skin symptoms predated and continued through treatment
• Timeline supporting delayed diagnosis or progression during the treatment period
• For ocular claims: serious documented eye injuries during use; and for all claims, viability under the state's limitations rules

How MTAA runs Dupixent campaigns

Early-tort advertising rewards education-led creative: the connection between an eczema drug and a lymphoma diagnosis is not one patients make on their own, so campaigns that explain the misdiagnosis pattern generate inquiries no competitor is yet contesting. The treated population is large, identifiable, and reachable through health-interest targeting.

MTAA is running Dupixent as an early-position campaign with screening built around the diagnosis-timeline questions that determine case viability.

Buying Dupixent case leads vs. running your own campaign

Most firms first see Dupixent offered by a vendor selling case leads or signed cases at a fixed price per case. That price bundles the advertising, the vendor's intake and the vendor's margin, and the firm usually cannot see which ad the claimant answered, what it promised, or what was said at signup.

Running your own Dupixent campaign turns that around. The firm pays the actual Meta media cost plus a 15% management fee, owns every signed retainer and its lead data, and can audit the ad, the landing page and the screening questions behind each claimant. When a defendant or a bar inquiry asks how a plaintiff was found, the firm has the record instead of a vendor's word.